MTOR and tuberous sclerosis: Vigabatrin, a GABA–transaminase inhibitor, is known to be particularly efficacious in TSC patients; in addition to elevating brain GABA levels by inhibiting enzymatic degradation of this substrate, it also inhibits mTOR pathway activity specifically [77].